CD8A and neoplasm: Our previous research (Liu et al., 2013) suggests that IL-27 significantly enhances the survival of tumor antigen specific CD8+ T cells in vivo, which indicates that AAV-IL-27 intra-tumoral administration could also be used as an adjuvant for T cell adoptive transfer therapy for cancer.